$5.74
25.05%
Nasdaq, Sep 02, 10:14 pm CET
ISIN
US56400P7069
Symbol
MNKD

MannKind Corporation Stock price

$5.74
+1.82 46.43% 1M
+0.61 11.89% 6M
-0.69 10.73% YTD
-0.52 8.31% 1Y
+1.96 51.85% 3Y
+4.08 245.78% 5Y
-13.51 70.18% 10Y
-56.86 90.83% 20Y
Nasdaq, Closing price Tue, Sep 02 2025
+1.15 25.05%
ISIN
US56400P7069
Symbol
MNKD
Industry

Key metrics

Basic
Market capitalization
$1.8b
Enterprise Value
$1.9b
Net debt
$111.4m
Cash
$179.0m
Shares outstanding
306.3m
Valuation (TTM | estimate)
P/E
52.2 | 42.4
P/S
5.8 | 5.4
EV/Sales
6.2 | 5.7
EV/FCF
65.0
P/B
negative
Financial Health
Equity Ratio
-20.0%
Return on Equity
-35.0%
ROCE
26.6%
ROIC
36.7%
Debt/Equity
-5.3
Financials (TTM | estimate)
Revenue
$301.7m | $327.0m
EBITDA
$88.1m | -
EBIT
$79.7m | $87.9m
Net Income
$32.3m | $41.5m
Free Cash Flow
$28.8m
Growth (TTM | estimate)
Revenue
21.5% | 14.5%
EBITDA
72.5% | -
EBIT
74.6% | 21.1%
Net Income
175.8% | 50.5%
Free Cash Flow
57.8%
Margin (TTM | estimate)
Gross
77.4%
EBITDA
29.2% | -
EBIT
26.4%
Net
10.7% | 12.7%
Free Cash Flow
9.5%
More
EPS
$0.1
FCF per Share
$0.1
Short interest
6.9%
Employees
405
Rev per Employee
$700.0k
Show more

Is MannKind Corporation a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,011 stocks worldwide.

MannKind Corporation Stock Analysis

Unlock Scores for Free

Analyst Opinions

14 Analysts have issued a MannKind Corporation forecast:

13x Buy
93%
1x Hold
7%

Analyst Opinions

14 Analysts have issued a MannKind Corporation forecast:

Buy
93%
Hold
7%

Financial data from MannKind Corporation

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
302 302
21% 21%
100%
- Direct Costs 68 68
3% 3%
23%
233 233
31% 31%
77%
- Selling and Administrative Expenses 105 105
15% 15%
35%
- Research and Development Expense 49 49
19% 19%
16%
88 88
72% 72%
29%
- Depreciation and Amortization 8.47 8.47
55% 55%
3%
EBIT (Operating Income) EBIT 80 80
75% 75%
26%
Net Profit 32 32
176% 176%
11%

In millions USD.

Don't miss a Thing! We will send you all news about MannKind Corporation directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

MannKind Corporation Stock News

Neutral
GlobeNewsWire
7 days ago
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Aug. 27, 2025 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of innovative inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, announced its participation at the upcoming investor conferences. MannKind's Chief Executive Officer Michael Cast...
Neutral
GlobeNewsWire
7 days ago
DANBURY, Conn. and BOSTON, Aug. 27, 2025 (GLOBE NEWSWIRE) --  MannKind Corporation (Nasdaq: MNKD) today announced that United Therapeutics Corporation (Nasdaq: UTHR) has exercised its option—granted under the companies' 2018 license and collaboration agreement—to develop a second dry powder inhalation therapy.
Neutral
Business Wire
8 days ago
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of scPharmaceuticals Inc. (NasdaqGS: SCPH) to MannKind Corporation (NasdaqGM: MNKD). Under the terms of the proposed transaction, shareholders of scPharmaceuticals would receive a cash payment of $5.35 per...
More MannKind Corporation News

Company Profile

MannKind Corp. is a biopharmaceutical company. It focuses on the discovery, development and, commercialization of therapeutic products for diseases, such as diabetes and cancer. The company was founded by Alfred E. Mann on February 14, 1991 and is headquartered in Westlake Village, CA.

Head office United States
CEO Michael Castagna
Employees 405
Founded 1991
Website mannkindcorp.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today